| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Outset Medical, Inc.$4.43
+0.09 (+2.08%)
F 16Pipeline Score MedTech · Commercial
Market Cap
79.99 M
EPS
-4.18
P/E Ratio
-
Value Trade
1.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
27.86 M
R&D Expenses
5.62 M
Operating CF
-12.84 M
Total Assets
249.45 M
Total Liabilities
137.77 M
Equity
111.69 M
D/E Ratio
12,345
16.76 %
Week
-4.42 %
1 Month
24.5 %
3 Month
-2.7 %
6 Month
-99.37 %
5 Year
-99.45 %
All Time
Cash Data
Cash Position
156.71 M
Monthly Burn
4.28 M
Runway
34.7 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
96.81 K
52 Week Range
3 - 21.98
% held by Insiders
5.96 %
% held by Institutions
83.16 %
Enterprise Value
24.90 M
Total Shares
18.31 M
Short %
8.98 %
Float Shares
16.63 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 794 of 911)
Percentile RankOutset Medical, Inc. has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OM▲ +8.8%on this news
Ryan ElliottVP Financial Planning & Analysis
The article provides a brief overview of key personnel at Outset Medical, including Ryan Elliott as VP of Financial Planning & Analysis. It lists other executives such as Leslie Trigg, Michael Aragon, and John Brottem, along with their respective roles and appointment dates. However, it lacks detailed information about their contributions or company developments.
Read more →OM▲ +9.1%on this newsshared move
Jaime PulidoSVP, Finance
The article presents a list of key personnel at Outset Medical, including Jaime Pulido as Senior Vice President of Finance. It also mentions Leslie Trigg as Chair and CEO, Michael Aragon as Chief Medical Officer, and John Brottem as General Counsel. The information appears to be part of a corporate announcement regarding leadership roles.
Read more →OMOutset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21, 2026
Outset Medical, Inc. has announced the approval of equity awards for two newly appointed non-executive employees as part of its Inducement Plan. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and involves the granting of 45,000 restricted stock units (RSUs) that will vest over three years. The company is recognized for its innovative Tablo® Hemodialysis System, which aims to enhance dialysis care.
Read more →OMOutset Medical to Present at RBC Global Healthcare Conference
Outset Medical, Inc. will participate in the RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company's innovative Tablo® Hemodialysis System is designed to enhance dialysis care by integrating water purification and dialysate production. This system is FDA-cleared and is already in use at over 1,000 healthcare facilities in the U.S.
Read more →OMOutset Medical Reports First-Quarter Results
Outset Medical, Inc. reported its financial results for the first quarter of 2026, revealing a net revenue of $27.9 million, representing a decline of 6% from the previous year. Despite the revenue decrease, the company achieved a gross margin of 43.4%, an increase of over 600 basis points compared to the same quarter in 2025. The net loss was reduced significantly, indicating an improvement in financial performance. Outset reiterated its revenue guidance for 2026, projecting a growth between 5% and 9% over 2025.
Read more →OMOutset Medical Reports First-Quarter Results San Jose, CA –
Outset Medical, Inc. reported its first quarter financial results for 2026, revealing a net revenue of $27.9 million, which reflects a 6% decline from the previous year. While recurring revenue remained stable at $22.5 million, the company achieved a gross margin expansion to 43.4%, marking significant progress in profitability. Operating expenses increased by 6%, driven by investments in systems and personnel, contributing to a net loss of $19 million, yet improved from the net loss recorded last year. Outset maintains its revenue guidance for 2026, projecting an increase of 5% to 9%, although challenges in product revenue persist.
Read more →OMOutset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
Outset Medical, Inc. will announce its financial results for Q1 2026 on May 7, 2026. The announcement will be followed by a conference call hosted by CEO Leslie Trigg and CFO Renee Gaeta. The company is known for its innovative Tablo® Hemodialysis System, which aims to improve dialysis care.
Read more →OMOutset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Outset Medical, Inc. has granted equity awards to its newly appointed Executive Vice President of Commercial, Derick Elliott, and another non-executive employee. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new hires. The awards consist of restricted stock units (RSUs) that will vest over three years.
Read more →OMOutset Medical Names Derick Elliott as Executive Vice President of Commercial
Outset Medical has appointed Derick Elliott as Executive Vice President of Commercial. Elliott, who has over 30 years of experience in sales and marketing, will oversee the company's commercial organizations. His previous roles include Chief Commercial Officer at SpendMend and various positions at Stryker and Cardinal Health. This appointment comes as Outset aims to expand its technology offerings in the dialysis sector.
Read more →OM▼ -16.3%on this news
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Outset Medical reported its financial results for Q4 and full year 2025, showing a 5% revenue increase to $119.5 million. Despite a slight revenue decline in Q4, the company improved its gross profit and reduced operating expenses significantly. The net loss decreased compared to the previous year, and the company provided optimistic revenue guidance for 2026.
Read more →OM▼ -11.5%on this news
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
Outset Medical's next-generation Tablo Hemodialysis System has received 510(k) clearance from the FDA, marking it as the first dialysis system to meet the agency's stringent cybersecurity standards. The new platform is designed to enhance security, reliability, and user experience, with shipping planned for the second quarter of 2026. Healthcare providers currently using Tablo will have the option to upgrade to this new system.
Read more →OM▲ +14.3%on this newsshared move
Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026
Outset Medical, Inc. will announce its fourth quarter and full-year 2025 financial results on February 11, 2026. The announcement will be followed by a conference call hosted by CEO Leslie Trigg and CFO Renee Gaeta. The company is known for its innovative Tablo® Hemodialysis System, which aims to simplify dialysis processes.
Read more →OM▼ -8.1%on this news
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
Outset Medical reported its unaudited revenue for Q4 and fiscal year 2025, highlighting a strong backlog and a positive outlook for 2026. The company also appointed Karen N. Prange to its board of directors, replacing Andrea Saia. Prange brings extensive experience in medical technology and leadership, which is expected to support Outset's growth strategy.
Read more →OM▲ +12.9%on this news
Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Outset Medical, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Leslie Trigg will discuss the company's innovative dialysis technology, the Tablo® Hemodialysis System, which is designed to reduce costs and complexity in dialysis care. The system is FDA-cleared and has been adopted by over 1,000 healthcare facilities in the U.S.
Read more →OM▼ -48.5%on this news· ran to -61% by day 3
Outset Medical Reports Third-Quarter Results
Outset Medical reported its third-quarter financial results for 2025, showing a 3% increase in revenue compared to the same quarter last year. However, the company revised its revenue guidance for the year downward, now expecting between $115 million and $120 million. Despite a reduction in operating expenses and an improvement in gross profit, the net loss remains significant. The CEO noted delays in closing large sales opportunities, which are now expected to finalize in early 2026.
Read more →OMOutset Medical Reports Third-Quarter Results San Jose, CA –
Outset Medical reported its financial results for Q3 2025, indicating a slight revenue growth of 3% year over year, with a net revenue of $29.4 million. The company also revised its 2025 revenue guidance downwards to a range of $115 million to $120 million. While gross margins improved and operating expenses declined nearly 20%, the CEO noted that expected sales closures have shifted into early 2026, indicating a potential delay in realizing revenue.
Read more →OM▼ -6%on this news· ran to -50% by day 3shared move
New Research Demonstrates the Advantages of an Insourced Dialysis Service Line for Acute-Care Facilities Using Outset Medical’s Tablo® Hemodialysis System
Outset Medical announced new research findings on its Tablo Hemodialysis System, showcasing over 1 million treatments and significant benefits from insourcing dialysis services. The results, which will be presented at the American Society of Nephrology's Kidney Week 2025, highlight improved patient outcomes and cost savings for hospitals. This research supports the adoption of insourced dialysis to enhance care for patients with renal issues.
Read more →OMOutset Medical to Present at the 2025 Stifel Healthcare Conference
Outset Medical, Inc. will present at the 2025 Stifel Healthcare Conference on November 12, 2025. The company focuses on innovative dialysis solutions, particularly the Tablo® Hemodialysis System, which integrates water purification and dialysate production. This system is designed to enhance operational and clinical outcomes in kidney care.
Read more →OMOutset Medical to Report Third Quarter 2025 Financial Results on Monday, November 10, 2025
Outset Medical, a leader in dialysis technology, will announce its third quarter 2025 financial results on November 10, 2025. CEO Leslie Trigg and CFO Renee Gaeta will host a conference call to discuss these results. The company's Tablo® Hemodialysis System is recognized for its innovative approach to dialysis care.
Read more →OMOUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Outset Medical, Inc. following a class action complaint. This complaint alleges that the company's directors may have breached fiduciary duties by making false statements and failing to disclose significant risks concerning its Tablo products. Specifically, issues related to FDA approval indications for the products and the firm's sales capabilities are highlighted as points of concern. Shareholders are encouraged to contact the law firm for inquiries or to provide information related to this case.
Read more →OMNorthwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis
Northwest Kidney Centers has partnered with Outset Medical to enhance home hemodialysis offerings by integrating the Tablo Hemodialysis System. This collaboration aims to improve patient independence and accessibility to treatment. The Tablo system is designed for ease of use, allowing patients to manage their dialysis with minimal infrastructure. Both organizations are committed to empowering patients through innovative technology.
Read more →OMOutset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
Outset Medical, Inc. will present at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 10, 2025. The company focuses on innovative dialysis technology, particularly the Tablo® Hemodialysis System, which simplifies the dialysis process. A live and archived webcast of the presentation will be available on their website.
Read more →OM▲ +7.7%on this news
Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization
Outset Medical reported strong financial results for Q2 2025, with revenue rising 15% to $31.4 million. The company achieved a gross margin of 37.8%, up from 35.7% in the previous year, and reduced operating expenses by 29%. Despite a net loss of $18.5 million, Outset raised its revenue guidance for 2025, reflecting ongoing demand for its Tablo system.
Read more →OMOutset Medical Names First Chief Nursing Officer
Outset Medical has appointed Brittni McGill as its first Chief Nursing Officer. McGill, with 18 years of nursing and executive experience, will focus on enhancing clinical programs and outreach for nurses. Her previous success in improving dialysis services is expected to benefit Outset's mission to enhance patient care and operational efficiency in dialysis.
Read more →OMOutset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Outset Medical, Inc. will announce its financial results for the second quarter of 2025 on August 6, 2025. The announcement will be followed by a conference call led by CEO Leslie Trigg and CFO Renee Gaeta to discuss these results. Outset develops innovative technology aimed at reducing the cost and complexity of dialysis, with its Tablo Hemodialysis System being a key product in this effort. This system enables dialysis treatment in various settings, enhancing accessibility and efficiency.
Read more →OMOutset Medical to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Outset Medical, Inc. will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The company is known for its innovative Tablo® Hemodialysis System, which aims to reduce the complexity and cost of dialysis. A live webcast of the presentation will be available on their website.
Read more →OM▲ +9%on this newsshared move
Outset Medical Appoints Renee Gaeta as Chief Financial Officer San Jose, CA
Outset Medical has announced the appointment of Renee Gaeta as the new Chief Financial Officer, effective immediately. Gaeta, who previously served as CFO at Shockwave Medical, brings significant financial leadership experience to the role. The company has reiterated its financial outlook for 2025, projecting revenues between $115 million and $125 million. This leadership change aims to support Outset's growth and profitability goals in pioneering innovative dialysis technology.
Read more →OM▲ +7.3%on this news
Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors San Jose, CA
Outset Medical has appointed Kevin O'Boyle to its Board of Directors and as chair of the Audit Committee. O'Boyle, a seasoned healthcare executive, has over 20 years of experience in healthcare leadership, including serving as CFO for various publicly traded companies. His extensive knowledge of capital equipment and business models aligns with Outset's growth objectives. Dale E. Jones has stepped down from the Board following O'Boyle's appointment.
Read more →OMOutset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined San Jose, CA –
Outset Medical, Inc. reported its first-quarter results for 2025, indicating a strong performance with a 6% increase in net revenue year-over-year, reaching $29.8 million. The company experienced a 20% growth in recurring revenue from Tablo products, signaling ongoing customer engagement. Additionally, gross margins expanded to 37.2%, reflecting improved operational efficiency. Despite a significant net loss, cash used in operations declined by 44%, showcasing better cash management and a strengthened financial position.
Read more →OMOutset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Outset Medical, Inc. (Nasdaq: OM) announced it will share its financial results for the first quarter of 2025 on May 7, 2025, after market close. CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call to discuss the results, which interested parties can join after registering online. Outset is known for its innovative Tablo Hemodialysis System, which aims to enhance the dialysis experience and reduce costs.
Read more →OMOutset Medical Announces One-for-Fifteen Reverse Stock Split San Jose, CA
Outset Medical, Inc. announced a one-for-fifteen reverse stock split that will become effective on March 20, 2025. Following the split, the number of outstanding shares will decrease from approximately 265 million to about 17 million. The company aims to simplify its stock structure while maintaining existing stockholder ownership percentages. This strategic move is expected to result in an adjusted trading price reflecting the reduced share count.
Read more →OM▼ -6.5%on this news· ran to -18% by day 3
Outset Medical, Inc. Index to Financial Statements Page Reports of Independent Registered Public Accounting Firm 2 Balance Sheets 6 Statements of Operations 7 Statements of Comprehensive Loss 8 Statements of Stockholders
Outset Medical, Inc. has released its financial statements for the period ending December 31, 2024. An independent registered public accounting firm has audited these statements and concluded that they fairly present the company's financial position and performance. The audit also included an evaluation of the effectiveness of the company's internal controls over financial reporting. The firm expressed an unqualified opinion on both the financial statements and internal controls, indicating no significant issues were found.
Read more →OM▼ -6.8%on this news· ran to -17% by day 3shared move
Outset Medical to Present at the 45th Annual TD Cowen Health Care Conference
Outset Medical, Inc. has announced that its management will present at the 45th annual TD Cowen Health Care Conference on March 4, 2025. The company focuses on pioneering technology to reduce the cost and complexity of dialysis through its Tablo® Hemodialysis System. This system is FDA cleared and facilitates dialysis from hospitals to home settings, allowing for operational efficiency and improved patient care.
Read more →OMOutset Medical Reports Fourth Quarter and Full Year 2024 Financial Results San Jose, CA –
Outset Medical, Inc. announced its financial results for Q4 and full year 2024, reporting net revenue of $29.5 million in Q4 and $113.7 million overall, both of which surpassed prior guidance. Despite a 13% year-over-year revenue decline, gross margins improved significantly to 33.9% for the year. The installation of the Tablo console reached nearly 6,000 units, and recurring revenue grew by 21%. However, the company reported a net loss of $128 million for the year, although this was an improvement over the previous year's loss.
Read more →OM▲ +5.1%on this news· ran to +21% by day 3shared move
Outset Medical Announces Resolution of Warning Letter
Outset Medical, Inc. has announced that it has resolved all issues related to a Warning Letter received from the FDA in July 2023. The company emphasizes its dedication to innovation and quality in providing dialysis technology. Leslie Trigg, CEO, stated that maintaining product quality and regulatory compliance is vital for the company's success. This resolution is viewed as an essential milestone in their commitment to improving outcomes for patients and providers in dialysis care.
Read more →OMOutset Medical to Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, February 19, 2025
Outset Medical, Inc. will report its financial results for the fourth quarter and full-year 2024 on February 19, 2025. Following the release, CEO Leslie Trigg and CFO Nabeel Ahmed will host a conference call to discuss the results. The company's Tablo® Hemodialysis System represents a significant advancement in dialysis technology, aimed at reducing costs and complexities in treatment.
Read more →OM▼ -11.2%on this news· ran to -26% by day 3
Outset Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Outset Medical, a company known for its innovative dialysis technology, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. Chair & CEO Leslie Trigg is scheduled for the presentation at 8:15 a.m. Pacific time. The company's Tablo Hemodialysis System has received FDA clearance and is designed to simplify dialysis cost and processes for providers and patients alike. An archived version of the presentation will be made available on Outset's investor relations website.
Read more →OM▼ -9.3%on this news· ran to -34% by day 3shared move
Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in
Outset Medical has announced a successful private placement financing totaling $169 million, funded by leading mutual funds and institutional investors. The company also secured new debt financing of up to $125 million maturing in 2030, aiming to retire $200 million in existing debt. This funding is anticipated to support Outset through a cash flow breakeven point, with fourth-quarter revenue for 2024 reported at $29 million, establishing a full year revenue of $113 million, surpassing previous estimates.
Read more →OM▼ -8%on this news· ran to -19% by day 1
Outset Medical to Present at the 2024 Stifel Healthcare Conference
Outset Medical, Inc. has announced a presentation at the 2024 Stifel Healthcare Conference, scheduled for November 19, 2024. The company's technology aims to revolutionize dialysis treatment by reducing costs and complexity through the Tablo® Hemodialysis System. This system allows for convenient dialysis delivery in various settings, from hospitals to home care. A live webcast of the presentation will be accessible via Outset's website, showcasing their innovations in dialysis care.
Read more →OMOutset Medical Reports Third Quarter 2024 Financial Results San Jose, CA –
Outset Medical reported a mixed financial performance for Q3 2024, with revenue of $28.7 million, representing a 5% increase from Q2 but a 6% decrease from Q3 2023. The company noted significant improvements in recurring revenue and gross margins compared to the previous year. However, the net loss was substantial at $27.9 million, although it was an improvement compared to the $46.2 million loss from the same quarter the prior year. The company has revised its 2024 revenue guidance upward, indicating some optimism despite ongoing challenges.
Read more →OM▼ -6.1%on this news
Outset Medical to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Outset Medical, Inc. is scheduled to release its third quarter 2024 financial results on November 6, 2024. Following the release, a conference call will be held at 2:00 p.m. Pacific time, hosted by CEO Leslie Trigg and CFO Nabeel Ahmed, to discuss the results. The Tablo® Hemodialysis System, designed to improve dialysis processes, highlights the company's innovative approach in medical technology.
Read more →OM▼ -6.1%on this news
Outset Medical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. Oct. 28, 2024 Deadline to file Lead Plaintiff Motion
Outset Medical, Inc. is facing a class action lawsuit from investors who allege that the company misled them regarding its Tablo Hemodialysis System. The lawsuit accuses Outset of failing to disclose important information about the product's FDA approval status and the associated risks, which led to significant financial losses for investors. The company has faced regulatory scrutiny and has reported disappointing financial results as a consequence of these issues. Investors must file a lead plaintiff motion by October 28, 2024, to recover their losses.
Read more →OMOutset Medical (OM) Shares Down 94% Since Disclosing FDA Warning Letter, Morgan Stanley And JPMorgan Chase Unload Most Of Their Positions In OM Shares - Hagens Berman
Outset Medical, Inc. (OM) is currently in jeopardy of being delisted from the Nasdaq due to its stock price falling below the required threshold for 30 consecutive trading days. The company is also facing a class-action lawsuit alleging it misled investors regarding its Tablo products and their FDA approval status. Since the issuance of an FDA warning letter last year, which reported improper promotion of the TabloCart, the company's share price has dropped dramatically by over 94%. Hagens Berman is investigating potential misconduct by Outset Medical related to these developments.
Read more →OMOutset Medical (OM) Receives Nasdaq Notice, Shares No Longer Meet Minimum Bid Requirement, Class Action Pending After FDA Warning - Hagens Berman
Outset Medical (NASDAQ: OM) has received notice from Nasdaq that it no longer meets the minimum bid price requirement due to its stock closing below $1.00 for 30 consecutive trading days. This follows significant declines in its stock price, which plummeted 94% since a warning letter from the FDA regarding its Tablo products. The company is currently under investigation for allegedly misleading investors about various operational issues, including sales practices and regulatory compliance, with a class action lawsuit pending. Financial results have also been disappointing, prompting a restructuring of the sales team and efforts to regain market confidence.
Read more →OMOutset Medical, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – OM
Outset Medical, Inc. is being sued for alleged securities law violations related to its Tablo dialysis products. The class action complaint claims that the company made misleading statements about the approval and marketing of these devices, which are not fully sanctioned by the FDA. Shareholders who purchased shares during the class period from August 1, 2022, to August 7, 2024, are encouraged to contact The Gross Law Firm for potential lead plaintiff appointments. The deadline for registering in the lawsuit is October 28, 2024.
Read more →OMOutset Medical (OM) Shares Down 94% Since Disclosing FDA Warning Letter, Class Action Pending - Hagens Berman
Outset Medical (OM) is currently facing a securities class action after announcing significant financial impacts stemming from an FDA warning letter received in July 2023. The warning letter indicated that the company may have been promoting its Tablo product without proper authorization, leading to a sharp decline in stock prices and a pausing of shipments. Further disappointing financial results announced in October 2023 and August 2024 confirmed the negative outlook, prompting an investigation into the company's disclosures to investors regarding its business prospects. As of now, shares are down 94% from their pre-warning price.
Read more →OMOutset Medical (OM) Faces Investor Scrutiny After FDA Warning Letter Leads to Poor Financial Results - Hagens Berman
Outset Medical (OM) is currently under investor scrutiny following a FDA warning letter that affects its Tablo Hemodialysis System. The company faced significant financial repercussions, reporting disappointing results for Q3 2023 and Q2 2024. This situation arose after it was revealed that the Tablo products were marketed incorrectly, leading to a cessation of sales and a need for restructuring within the company. Legal action has been initiated regarding potential misleading disclosures related to the Tablo product's marketing and sales strategy.
Read more →OMOutset Medical, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. Oct. 28, 2024 Deadline to file Lead Plaintiff Motion.
Outset Medical, Inc. is under scrutiny due to a class action lawsuit filed by investors who allege the company made misleading claims about its Tablo Hemodialysis System. The lawsuit points out that Tablo products were marketed for unapproved uses and highlights various operational disclosures that were not made public. The situation worsened when Outset revealed an FDA warning letter concerning unauthorized promotions and subsequently suspended shipments of its TabloCart. As a result, the company has reported disappointing financial results and guided for slowed growth moving forward.
Read more →OMOUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Outset Medical, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been initiated against Outset Medical, alleging that the company made false statements regarding its Tablo products during the period from August 1, 2022, to August 7, 2024. The lawsuit claims that marketing the Tablo products for unapproved uses could lead to a halt in sales pending FDA approval. Furthermore, it alleges that the company lacks an adequate sales team to support its growth trajectory. Investors have until October 28, 2024, to apply as lead plaintiffs in the case.
Read more →OMOutset Medical, Inc. (OM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims related to Outset Medical, Inc. after the company reported second quarter financial results that significantly missed consensus estimates and lowered its full year outlook. This disappointing financial performance led to shares of Outset falling by 68.53% in a single day. Investors are encouraged to participate in the investigation, and the firm is representing them on a contingency basis. The investigation aims to uncover any potential wrongdoings that may have affected stock performance.
Read more →OMOUTSET ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Outset Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Outset Medical, Inc. on behalf of its stockholders over potential violations of federal securities laws. The investigation follows Outset's disappointing second quarter 2024 financial results, which included a substantial miss of market expectations and a revised negative outlook for the year. After the news, Outset's stock experienced a significant decline of 68.53%. The firm is reaching out to affected investors to assist in exploring these claims.
Read more →OMOutset Medical Reports Second Quarter 2024 Financial Results San Jose, CA –
Outset Medical, Inc. reported its second quarter financial results for 2024, highlighting record treatment levels using its Tablo hemodialysis system. Despite high demand and a significant rise in gross margin, the company experienced a decline in revenue and below-expected console placements. Operating expenses decreased substantially, but the company still recorded a notable net loss. Outset has adjusted its full-year revenue guidance downwards, reflecting challenges in meeting initial forecasts.
Read more →OM▲ +9%on this news
Outset Medical Reports First Quarter 2024 Financial Results San Jose, CA –
Outset Medical reported its financial results for the first quarter of 2024, revealing a revenue decline to $28.2 million from $33.5 million in Q1 2023. Despite this, the company noted its 12th consecutive quarter of gross margin expansion and significant growth in service revenue. Outset's ongoing cost-reduction efforts aim to achieve profitability without seeking additional capital, while their sales pipeline remains strong. The company reaffirmed guidance for continued growth in revenue throughout the year.
Read more →OM▲ +20.7%on this newsshared move
Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance SAN JOSE, Calif. –
Outset Medical, Inc. announced FDA 510(k) clearance for its TabloCart with prefiltration, enhancing the functionality of the Tablo Hemodialysis System. The new accessory facilitates flexible dialysis delivery, adaptable to a range of clinical environments. With features such as customizable prefiltration and improved mobility, TabloCart aims to simplify the operational process for healthcare providers. Outset has resumed distribution of the product across the United States, marking a significant step in their commitment to innovation in dialysis treatment.
Read more →OMOutset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors San Jose, CA
Outset Medical has appointed Brent D. Lang, a seasoned medical technology executive, to its board of directors. Lang, who previously served as Chairman and CEO of Vocera Communications, brings substantial expertise in software-enabled business models, which aligns with Outset’s revenue strategies. His role on the board aims to guide the company's growth and support its mission in improving the dialysis experience. Concurrently, Katie M. Szyman stepped down from the board to advance her career as CEO of Edwards Lifesciences' Critical Care spinoff.
Read more →OMOutset Medical Reports Fourth Quarter and Full Year 2023 Financial Results San Jose, CA –
Outset Medical reported its financial results for the fourth quarter and full year 2023, showing a revenue increase of 13% year-over-year to $130.4 million. Notably, the company achieved a significant improvement in gross margin to 25.3% in the fourth quarter, marking a substantial growth from 16.5% in the prior year. However, the company also reported a net loss of $38.6 million for the quarter. The installed base of its Tablo dialysis consoles grew by 34%, with recurring revenue making up over 50% of its total revenue.
Read more →OMOutset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance San Jose, CA
Outset Medical reported its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023, revealing a revenue increase to $130 million. The installed base of Tablo Hemodialysis Systems grew 34% year-over-year, demonstrating market acceptance. Additionally, the company forecasts 2024 revenues to range from $145 million to $153 million, highlighting anticipated growth. Outset also provided guidance on expanding non-GAAP gross margins as it continues to capitalize on its unique dialysis technology.
Read more →OMOutset Medical (OM) Investigated for Possible Securities Law Violations: Hagens Berman, National Trial Attorneys, Encourages Investors with Losses to Contact the Firm’s Attorneys
Outset Medical (NASDAQ: OM) is currently facing an investigation led by Hagens Berman concerning potential securities law violations related to the marketing of its Tablo Hemodialysis System. The investigation arises after the company received an FDA Warning Letter and subsequently reported lower-than-expected revenues, attributing the decline to impacts from regulatory issues. Additionally, the company's stock has seen a sharp decrease, prompting at least one analyst to double downgrade their shares. Investors who have incurred losses are encouraged to contact Hagens Berman for assistance.
Read more →OMOutset Medical Reports Third Quarter 2023 Financial Results Reiterates Updated 2023 Revenue Guidance of Approximately $130 Million San Jose, CA –
Outset Medical, Inc. announced its financial results for the third quarter of 2023, reporting a revenue increase to $30.4 million, up 9% from the prior year. The company reiterated its revenue guidance of approximately $130 million for the full year. However, it also reported a net loss of ($46.2) million, which signifies ongoing financial difficulties despite improvements in gross margin. The company's operating expenses have escalated compared to the previous year, raising concerns about its financial sustainability moving forward.
Read more →OM▲ +15.3%on this news· ran to +38% by day 3
Outset Medical (OM) Investigated for Possible Securities Law Violations: Hagens Berman, National Trial Attorneys, Encourages Investors with Losses to Contact the Firm
Outset Medical, Inc. (NASDAQ: OM) is being investigated by Hagens Berman for potential securities law violations related to its flagship dialysis device, Tablo. The firm has urged investors who incurred losses to come forward. The investigation centers on disclosures concerning marketing authorizations for Tablo, particularly following an FDA Warning Letter regarding misleading claims and the need for additional marketing authorization. Q3 2023 revenues were disappointing, prompting the company to reduce its revenue guidance significantly, leading to a notable decline in stock price.
Read more →OM▼ -6.7%on this news· ran to -18% by day 3
Outset Medical (PM) Investigated for Possible Securities Law Violations, Hagens Berman Encourages Investors with Losses to Contact its Attorneys
Outset Medical, Inc. (NASDAQ: OM) is currently being investigated by Hagens Berman for possible securities law violations, particularly relating to its disclosures about the Tablo Hemodialysis System. The investigation began following the company's announcement of a shipment hold and issues with its 510(k) application, which led to a suspension of financial guidance. Further complications arose when the FDA issued a warning letter, resulting in disappointing preliminary revenues for Q3 2023 and a reduced revenue outlook for the fiscal year. The situation has caused significant drops in share prices and prompted aggressive analyst ratings downgrades.
Read more →OMOutset Medical, Inc.: Company Investigated by the Portnoy Law Firm
Outset Medical, Inc. is under investigation by the Portnoy Law Firm for potential securities violations following a decline in stock price. The investigation comes after the company received a Warning Letter from the FDA regarding improper promotion of its Tablo Hemodialysis System. As a result, investors have experienced financial losses, prompting the law firm to seek class action claims on their behalf.
Read more →OM▼ -49.9%on this newsshared move
“Outset Medical stock nosedives due to FDA warning letter headwinds” – Hagens Berman
Outset Medical, Inc. (NASDAQ: OM) is facing significant challenges after receiving an FDA Warning Letter concerning its Tablo Hemodialysis System. The FDA's letter highlighted issues with the company's website promoting unapproved uses and indicated that another marketing authorization was needed. Consequently, Outset reported disappointing preliminary Q3 2023 revenues and reduced its FY 2023 revenue guidance, citing the negative impact of the FDA warning on their sales cycle. As a result, the company's stock has plummeted, triggering investigations into potential misleading disclosures made to investors.
Read more →OM▼ -11.3%on this news· ran to -56% by day 1shared move
Outset Medical Reports Preliminary Third Quarter 2023 Financial Results Conference Call Scheduled for 4:30 p.m. ET San Jose, CA –
Outset Medical, Inc. reported preliminary financial results for the third quarter of 2023, with revenue reaching $30.4 million, marking a 9% increase from the previous year. The company raised its revenue guidance for 2023 to approximately $130 million, supported by a solid cash position of $197 million. However, the growth has been tempered by challenges, including a significant impact from a recent FDA warning letter and emerging caution in capital spending. Despite these challenges, the CEO remains confident in the company's long-term growth prospects.
Read more →OMOutset Medical Reports Second Quarter 2023 Financial Results Sequential Revenue Growth of 8%, Ninth Consecutive Quarter of Gross Margin Expansion Announces Shipment Pause of TabloCart with Prefiltration Pending 510(k) Cl
Outset Medical reported a 44% increase in revenue for the second quarter of 2023 compared to the previous year, marking an 8% increase sequentially. The company experienced its ninth consecutive quarter of gross margin expansion and initiated its first Tablo home dialysis program with a large U.S. health system. However, the shipment of the TabloCart accessory has been paused pending FDA clearance, leading the company to forecast revenue at the lower end of its guidance range for 2023.
Read more →OMOutset Medical Reports First Quarter 2023 Financial Results Increases Revenue and Gross Margin Guidance for 2023 San Jose, CA –
Outset Medical, Inc. reported its first quarter 2023 financial results, showing a 9.5% increase in net revenue to $33.5 million and an improvement in gross margin to 19.2%. The company added over 30 new hospital sites, marking significant growth in its commercial strategy. However, net loss increased to $44 million, reflecting higher operating expenses which reached $49.9 million. Outset has adjusted its full-year revenue guidance upwards, now expecting a 25% to 30% growth compared to the previous year.
Read more →OMOutset Medical Reports Fourth Quarter and Full Year 2022 Financial Results San Jose, CA –
Outset Medical, Inc. reported its financial results for Q4 and full year 2022, showcasing revenue growth of 14.0% in Q4 compared to the same quarter in 2021. The company's gross margin improved significantly, bolstered by a 54% increase in the installed base of its Tablo systems. Despite achieving notable revenue gains, net losses expanded for both the quarter and the year. Looking ahead, Outset maintains its 2023 revenue guidance, forecasting continued growth in line with past performance.
Read more →OMOutset Medical Reports Expected Fourth Quarter and Full Year 2022 Revenue, Provides 2023 Revenue and non-GAAP Gross Margin Guidance San Jose, CA –
Outset Medical reported strong expected revenue growth for the fourth quarter and full year of 2022, with anticipated revenues of about $31.5 million and $115 million respectively. The company also forecasted significant revenue growth for 2023, projecting revenues between $140 million and $150 million. A notable installed base increase of 54% for Tablo Hemodialysis Systems was also highlighted. Management expressed confidence in the company's momentum heading into 2023, while emphasizing recent innovations and improvements.
Read more →OM▼ -7.5%on this news· ran to +44% by day 3
Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA –
Outset Medical Reports Third Quarter 2022 Financial Results Revenue Grows 10.8% from Q2 to $27.8 million; Gross Margin Expands to 15.6% 2022 Revenue Guidance Raised to $111 million to $113 million San Jose, CA November 8, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset or the
Read more →OMOutset Medical Secures Up To $300 Million in Debt Financing San Jose, CA –
Outset Medical Secures Up To $300 Million in Debt Financing San Jose, CA November 4, 2022 -- Outset Medical, Inc. (Nasdaq: OM)( Outset ), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it
Read more →OMOutset Medical, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. (“Outset” or the “Company”) (Nasdaq: OM) investors that a class action has been filed on be
Read more →OMOUTSET MEDICAL, INC. (NASDAQ: OM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Outset Medical, Inc. (NASDAQ: OM)
Did you lose money on investments in Outset Medical? If so, please visit Outset Medical, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebh
Read more →OMOUTSET MEDICAL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Outset Medical, Inc. - OM
NEW ORLEANS, Aug. 30, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 6, 2022 to file lead plaintiff applications in a securities class action lawsuit against Outset Medical, Inc. (“Outset” or the “Com
Read more →OMOUTSET MEDICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Outset Medical, Inc. - OM
NEW ORLEANS, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 6, 2022 to file lead plaintiff applications in a securities class action laws
Read more →OMOUTSET MEDICAL LAWSUIT ALERT: Kaplan Fox & Kilshiemer LLP Notifies Outset Medical Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical” or the "Company”) (NASDAQ: OM). Outset Medical is a medical technology company that distributes the
Read more →OMOutset Medical Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA ȁ
Outset Medical Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA August 1, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset or th
Read more →OMOutset Medical, Inc. Shareholder Update: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Outset Medical, Inc. (OM)
SAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of investors who purchased Outset Medical, Inc. (NASDAQ: OM) common stock between September 15, 2020 and June 13, 2
Read more →OMOUTSET MEDICAL, INC. (NASDAQ: OM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Outset Medical, Inc. (NASDAQ: OM)
Did you lose money on investments in Outset Medical? If so, please visit Outset Medical, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebha
Read more →OMOutset Medical, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, June 29, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Outset Medical, Inc. (NASDAQ: OM) for potential securities law violations. Investors who have lost money in their Outset Medical, Inc. investment should contact the firm to learn more about how they might
Read more →OMOutset Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) investors that the firm has initiated an investiga
Read more →OMOutset Medical Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Outset Medical, Inc.
NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset Medical” or the "Company”) (NASDAQ: OM). Outset Medical is a medical technology company that develops a hemo
Read more →OMOutset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA –
Outset Medical Announces Shipment Hold on New Tablo Systems for Home Use Pending FDA Review and Clearance of Recent 510(K) Submission Investor Webcast and Conference Call Scheduled for 5:00 p.m. EST San Jose, CA June 13, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset or the co
Read more →OMOutset Medical Reports First Quarter 2022 Financial Results Revenue Grows 33.3% to $30.6 million, Gross Margin expands 13.2 percentage points to 14.5% Year-over-Year San Jose, CA –
Outset Medical Reports First Quarter 2022 Financial Results Revenue Grows 33.3% to $30.6 million, Gross Margin expands 13.2 percentage points to 14.5% Year-over-Year San Jose, CA May 4, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset or the Company ), a medical technology compa
Read more →OMOutset Medical Names Business Leader Dale E. Jones to Board of Directors San Jose, CA –
Outset Medical Names Business Leader Dale E. Jones to Board of Directors San Jose, CA April 25, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset ), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its B
Read more →OMOutset Medical Reports Fourth Quarter and Full Year 2021 Financial Results Record Annual Revenue of $102.6 Million; 105% Year-over-Year Growth San Jose, CA –
Outset Medical Reports Fourth Quarter and Full Year 2021 Financial Results Record Annual Revenue of $102.6 Million; 105% Year-over-Year Growth San Jose, CA February 16, 2022 Outset Medical, Inc. (Nasdaq: OM) ( Outset or the Company ), a medical technology company pioneering a f
Read more →OMOutset Medical Reports Third Quarter 2021 Financial Results 2021 Revenue Guidance Range Elevated to $99 million to $101 million San Jose, CA –
Outset Medical Reports Third Quarter 2021 Financial Results 2021 Revenue Guidance Range Elevated to $99 million to $101 million San Jose, CA November 3, 2021 Outset Medical, Inc. (Nasdaq: OM) ( Outset or the Company ), a medical technology company pioneering a first-of-its-kind
Read more →OMOutset Medical Reports Second Quarter 2021 Financial Results 2021 Revenue Guidance Range Updated to $97 million to $100 million San Jose, CA
Outset Medical Reports Second Quarter 2021 Financial Results 2021 Revenue Guidance Range Updated to $97 million to $100 million San Jose, CA - August 5, 2021 - Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-
Read more →OMOutset Medical Announces Departure of CFO and Appointment of Nabeel Ahmed as Interim CFO Reports Preliminary Results for Second Quarter 2021 San Jose, CA
Outset Medical Announces Departure of CFO and Appointment of Nabeel Ahmed as Interim CFO Reports Preliminary Results for Second Quarter 2021 San Jose, CA July 1, 2021 Outset Medical, Inc. (Nasdaq: OM) ( Outset ), a medical technology company pioneering a first-of-its-kind techn
Read more →OMOutset Medical Appoints MedTech Executive Katie Szyman to Board of Directors
Outset Medical Appoints MedTech Executive Katie Szyman to Board of Directors SAN JOSE, Calif. - May 24, 2021 - Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today a
Read more →OMOutset Medical Reports First Quarter 2021 Financial Results San Jose, CA
Outset Medical Reports First Quarter 2021 Financial Results San Jose, CA - May 5, 2021 - Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today rep
Read more →OMOutset Medical Announces Pricing of Primary and Upsized Secondary Public Offering
Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering SAN JOSE, Calif. (BUSINESS WIRE) Apr. 9, 2021 Outset Medical, Inc. (Nasdaq: OM) ( Outset ), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity
Read more →OMOutset Medical Announces Primary and Secondary Offering of Common Stock San Jose, CA
Outset Medical Announces Primary and Secondary Offering of Common Stock San Jose, CA April 6, 2021 Outset Medical, Inc. (Nasdaq: OM) ( Outset ), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today
Read more →OMOutset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors
Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors SAN JOSE, Calif. - March 24, 2021 - Outset Medical, Inc. (Nasdaq: OM) ("Outset"), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to re
Read more →OMOutset Medical Reports Fourth Quarter and Full Year 2020 Financial Results San Jose, CA
Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results San Jose, CA - March 9, 2021 - Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today rep
Read more →OMOutset Medical Appoints Karen Drexler to Board of Directors Healthcare Industry Veteran Brings Digital Health Expertise and Consumer-Centric Approach to Furthering Company's Mission of Transforming Dialysis Treatment
Outset Medical Appoints Karen Drexler to Board of Directors Healthcare Industry Veteran Brings Digital Health Expertise and Consumer-Centric Approach to Furthering Company's Mission of Transforming Dialysis Treatment SAN JOSE, Calif. - Jan. 12, 2021 - Outset Medical, Inc. (Nasd
Read more →OMOutset Medical Announces Secondary Offering of Common Stock San Jose, CA
Outset Medical Announces Secondary Offering of Common Stock San Jose, CA November 30, 2020 Outset Medical, Inc. (Nasdaq: OM) ( Outset ), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the comm
Read more →OMOutset Medical Reports Third Quarter 2020 Financial Results Strong Quarter Driven by Accelerating Acute Market Penetration and Significant Margin Expansion San Jose, CA
Outset Medical Reports Third Quarter 2020 Financial Results Strong Quarter Driven by Accelerating Acute Market Penetration and Significant Margin Expansion San Jose, CA - November 11, 2020 - Outset Medical, Inc. (Nasdaq: OM) ("Outset"), a medical technology company pioneering a
Read more →Competitive Position
How OM ranks across every disease it competes inCompetitive Position is a premium feature
See how OM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial